News · 26 weeks57-11%
2025-12-142026-06-07
Mix4190d
- Insider22(54%)
- SEC Filings15(37%)
- Offering1(2%)
- Earnings1(2%)
- Leadership1(2%)
- Analyst1(2%)
Latest news
25 items- SECSera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- INSIDERSEC Form 4 filed by Director Elliott Jeffrey Thomas4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- ANALYSTCraig Hallum initiated coverage on Sera Prognostics with a new price targetCraig Hallum initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $6.00
- INSIDERGeneral Counsel Jackson Benjamin was granted 5,000 shares, increasing direct ownership by 3% to 163,935 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Commercial Officer Anderson Dyaarl Lee Jr. was granted 3,168 shares, increasing direct ownership by 4% to 82,737 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSEC Form DEFA14A filed by Sera Prognostics Inc.DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS ANNOUNCES BOARD TRANSITIONSALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Comp
- INSIDERSEC Form 4 filed by Chief Data Officer Kearney Paul4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 4 filed by Chief Information Officer Harrison Robert Gardner4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Boniface John J.4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSEC Form 10-Q filed by Sera Prognostics Inc.10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form DEFA14A filed by Sera Prognostics Inc.DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form DEF 14A filed by Sera Prognostics Inc.DEF 14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- SECSEC Form 144 filed by Sera Prognostics Inc.144 - SERA PROGNOSTICS, INC. (0001534969) (Subject)
- SECSEC Form 424B5 filed by Sera Prognostics Inc.424B5 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form S-8 filed by Sera Prognostics Inc.S-8 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSEC Form 10-K filed by Sera Prognostics Inc.10-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTSSALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights:Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women,
- INSIDERChief Executive Officer Lindgardt Zhenya was granted 154,440 shares, increasing direct ownership by 21% to 892,754 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin was granted 44,215 shares, increasing direct ownership by 39% to 158,935 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
SERA FAQ
7 questionsWhat does Sera Prognostics Inc. do?
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Where does SERA stock trade?
Sera Prognostics Inc. (SERA) is listed on NASDAQ.What sector and industry is SERA in?
Sera Prognostics Inc. operates in the Health Care sector, Medical Specialities industry.When did Sera Prognostics Inc. go public?
Sera Prognostics Inc. (SERA) completed its IPO in 2021.What are analysts saying about SERA?
Sera Prognostics Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $600.00 price target on 2026-06-04. Recent price targets range from $400.00 to $1900.00.What companies are similar to SERA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare SERA side-by-side with any of them on Quantisnow.How can I track SERA on Quantisnow?
Quantisnow aggregates Sera Prognostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SERA to receive live email and push alerts on every new disclosure.